Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia

Conclusions: Selinexor, at a doses of 30 or 40 mg/m2 given twice weekly, was well tolerated in pediatric and young adult pts with R/R acute leukemia, demonstrating single agent clinical activity and less GI toxicity than had been seen in adults. The high frequency of TLS in ALL pts is particularly notable as treatment of ALL with selinexor has not been previously reported. Analysis of pharmacokinetic and correlative biology studies are underway. Based on the results of this Phase I study, the recommended Phase II dose of single-agent selinexor in children with R/R acute leukemia is 40 mg/m2 administered twice weekly. These results also support the continued investigation of selinexor in combination with multiagent chemotherapy.DisclosuresBurke: AMGEN: Speakers Bureau; JAZZ: Speakers Bureau; Shire: Speakers Bureau.

Source: Blood - November 21, 2018 Category: Hematology Authors: Place, A. E., Blonquist, T. M., Stieglitz, E., Cooper, T. M., Gore, L., Aplenc, R., Loh, M. L., Pauly, M., Rau, R. E., Burke, M. J., Etchin, J., Look, A. T., Sulis, M. L., Silverman, L. B. Tags: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I Source Type: research